There is an unmet need to identify non-invasive neuroimaging biomarkers to predict survival duration for NSCLC patients with brain metastases who may have one of the three most common mutations, i.e., EGFR, ALK, or KRAS. The gene discussed is ALK; the disease is non-small cell lung carcinoma.